Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
Gut and Liver
;
: 324-330, 2018.
Article
in English
| WPRIM
| ID: wpr-714608
ABSTRACT
BACKGROUND/AIMS:
The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness and noninvasive fibrosis markers, and the safety of DCV+ASV treatment in Korean patients.METHODS:
In total, 363 patients with chronic hepatitis C were treated with DCV+ASV between August 2015 and January 2017. Finally, we analyzed the data of 270 patients who were monitored for at least 12 weeks after the end of treatment.RESULTS:
The mean age was 60.7 years, and females predominated (60.4%). Most patients (64.8%) were treatment-naïve, and 56 patients (20.7%) had cirrhosis. Two hundred fifty-seven (95.2%) and 251 (93.0%) patients achieved end-of-treatment responses and sustained virological responses at 12 weeks posttreatment (SVR12), respectively. The SVR12 rates were higher in patients who were < 65 years of age, males, without cirrhosis and had lower HCV RNA levels. All LS values and fibrosis-4 and aspartate aminotransferase-to-platelet ratio index values declined from baseline to the time of assessment of SVR12.CONCLUSIONS:
The DCV+ASV therapy resulted in a high SVR12 and improved liver fibrosis; the treatment was well tolerated in patients with genotype 1b HCV infections.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Fibrosis
/
RNA
/
Hepatitis C
/
Aspartic Acid
/
Hepacivirus
/
Hepatitis C, Chronic
/
Genotype
/
Hepatitis
/
Liver
/
Liver Cirrhosis
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
Gut and Liver
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS